Eduard J van Beers, Hanny Al-Samkari, Rachael F Grace, Wilma Barcellini, Andreas Glenthøj, Melissa DiBacco, Megan Wind-Rotolo, Rengyi Xu, Vanessa Beynon, Parija Patel, John B Porter, Kevin H M Kuo
Pyruvate kinase (PK) deficiency is a rare, hereditary disease characterized by chronic hemolytic anemia. Iron overload is a common complication regardless of age, genotype, or transfusion history. Mitapivat, an oral, allosteric PK activator, improves anemia and hemolysis in adult patients with PK deficiency. Mitapivat's impact on iron overload and ineffective erythropoiesis was evaluated in adults with PK deficiency who were not regularly transfused in the phase 3 ACTIVATE trial and long-term extension (LTE) (NCT03548220/NCT03853798)...
February 8, 2024: Blood Advances